SLIF-06 is under clinical development by Scarless Laboratories and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect SLIF-06’s likelihood of approval (LoA) and phase transition for Hypertrophic Scars took place on 29 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 29 Nov 2022 increased SLIF-06’s Phase Transition Success Rate (PTSR) for Wounds.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SLIF-06 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

SLIF-06 overview

F06-C40 is under investigation for the treatment of hypertrophic scars, diabetic foot ulcers and wounds. The drug candidate consists of a synthetic 40 amino acid fibromodulin (FMOD) peptide sequence. Fibromodulin is a member of small leucine rich proteoglycan (SLRP) family. It is is a cytosolic secreted protein with an expression pattern restricted mainly to cartilage, bone, connective tissue, and tissue rich in collagen. It is involved in fibrillogenesis, cell adhesion, and cytokine activity modulation. It reduces the scar without compromising wound strength. It is administered through parenteral route.

Quick View SLIF-06 LOA Data

Report Segments
  • Innovator
Drug Name
  • SLIF-06
Administration Pathway
  • Parenteral
Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.